2/4
08:29 am
zvra
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ [Yahoo! Finance]
Medium
Report
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ [Yahoo! Finance]
2/4
07:30 am
zvra
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Low
Report
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
2/2
07:41 am
zvra
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 [Yahoo! Finance]
Medium
Report
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 [Yahoo! Finance]
2/2
07:30 am
zvra
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Medium
Report
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
1/26
07:30 am
zvra
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Low
Report
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
1/24
07:11 pm
zvra
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain [Yahoo! Finance]
Low
Report
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain [Yahoo! Finance]
1/13
04:06 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
1/8
07:30 am
zvra
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Low
Report
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
1/3
07:27 am
zvra
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]
Medium
Report
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]
12/30
09:08 am
zvra
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.
Low
Report
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.
12/29
07:30 am
zvra
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
Low
Report
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
12/14
05:24 am
zvra
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]
Low
Report
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]
12/14
03:09 am
zvra
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? [Yahoo! Finance]
Low
Report
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? [Yahoo! Finance]
12/12
04:30 pm
zvra
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/2
07:30 am
zvra
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Low
Report
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
11/20
04:37 pm
zvra
Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]
Medium
Report
Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]
11/20
04:31 pm
zvra
Zevra Therapeutics announces CFO transition [Seeking Alpha]
Medium
Report
Zevra Therapeutics announces CFO transition [Seeking Alpha]
11/20
04:05 pm
zvra
Zevra Therapeutics, Inc. Announces CFO Transition
Medium
Report
Zevra Therapeutics, Inc. Announces CFO Transition